NCT00855517View on ClinicalTrials.gov

A Phase 2 Study of the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2009

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
GlaucomaOcular Hypertension
Interventions
DRUG

Latanoprost-PPDS

Control of IOP compared to baseline for the experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.

Sponsors
All Listed Sponsors
lead

Mati Therapeutics Inc.

INDUSTRY

NCT00855517 - A Phase 2 Study of the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma | Biotech Hunter | Biotech Hunter